Tenofovir Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, & Pharmacodynamics (DREAM 01)

By sjmartinez • November 30, 2023

Weld ED, McGowan I, Anton P, Fuchs EJ, Ho K, Carballo-Dieguez A, Rohan LC, Giguere R, Brand R, Edick S, Bakshi RP, Parsons T, Manohar M, Seigel A, Engstrom J, Elliott J, Jacobson C, Bagia C, Wang L, Al-Khouja A, Hartman DJ, Bumpus NN, Spiegel HML, Marzinke MA, Hendrix CW. Tenofovir Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, & Pharmacodynamics (DREAM 01). J Infect Dis. 2023 Nov 29:jiad535. doi: 10.1093/infdis/jiad535. Epub ahead of print. PMID: 38019657.

Tags: Digestive Diseases, HIV, Infectious Diseases, Microbicide, Pharmacodynamics, Pharmacokinetics, phase I, Pre-exposure prophylaxis, Publications

Earlier initiation of tenofovir in pregnancy with infant hepatitis B vaccination obviates the need for hepatitis B immune globulin

Pak K, Saab S. Earlier initiation of tenofovir in pregnancy with infant hepatitis B vaccination obviates the need for hepatitis B immune globulin. Transl Gastroenterol[...]

International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung Disease

Andréasson K, Young A, Joshi S, Labus JS, Low AHL, Smith V, McMahan Z, Proudman S, Valenzuela A, Hunter P, Kim GH, Bozovic G, Goldin[...]

Population Health Colorectal Cancer Screening Strategies in Adults Aged 45 to 49 Years: A Randomized Clinical Trial

Galoosian A, Dai H, Croymans D, Saccardo S, Fox CR, Goshgarian G, De Silva S, Han MA, Vangala S, May FP. Population Health Colorectal Cancer[...]